Skip to main content
Chabiotech Co.,Ltd. logo

Chabiotech Co.,Ltd. — Investor Relations & Filings

Ticker · 085660 ISIN · KR7085660009 KO Professional, scientific and technical activities
Open in API
Filings indexed 460 across all filing types
Latest filing 2025-12-23 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 085660

About Chabiotech Co.,Ltd.

http://en.chabio.com/

Chabiotech Co., Ltd. is a biotechnology company specializing in the research and development of cell and gene therapies for rare cancers and incurable diseases. The company's core activities include advancing its therapeutic pipelines and providing global Contract Development and Manufacturing Organization (CDMO) services for advanced biopharmaceuticals, including full-scale GMP production and testing. Chabiotech also operates bio-banking services, such as cord blood and immune/stem cell storage, utilizing advanced cryopreservation technology. Its diversified business segments extend to genomics for precision medicine, healthcare IT solutions that integrate AI and Big Data, comprehensive wellness programs, and specialized healthcare consulting.

Recent filings

Filing Released Lang Actions
증권발행결과(자율공시)
Share Issue/Capital Change Classification · 100% confidence The document is a formal announcement regarding the results of a securities issuance (specifically a third-party paid-in capital increase) by Cha Biotech. It details the number of shares issued, the total amount raised, and the payment date. This falls under the category of share issuance and capital changes.
2025-12-23 Korean
주권관련사채권의취득결정
Capital/Financing Update Classification · 98% confidence The document is a formal regulatory filing from the Korean DART system titled '주권 관련 사채권의 취득결정' (Decision to Acquire Equity-Related Bonds). It details the acquisition of convertible bonds issued by a subsidiary (Cha Cares) by the parent company (Cha Biotech). This type of disclosure regarding capital allocation, financing, and investment in subsidiaries is classified as a general regulatory filing (RNS) in the absence of a more specific category like M&A or Share Issue, as it represents a corporate action disclosure.
2025-12-22 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a regulatory filing required under the Capital Markets Act in South Korea when a person or entity acquires a significant stake (typically 5% or more) in a company. This document details the shareholding status, changes in ownership, and major contracts (such as stock collateral agreements) of the reporting person (Cha Kwang-yul) and his special related parties in the company 'Cha Biotech'. This falls under the category of 'Major Shareholding Notification'.
2025-12-18 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is titled '주식등의 대량보유상황보고서' which translates to 'Report on Large Shareholding Status'. It contains detailed information about the number of shares held by a major shareholder and related parties, their ownership percentages, and details about stock pledge contracts. The document references the Capital Markets Act and includes data on shareholding changes and related contracts. This type of filing corresponds to notifications about major shareholding changes or disclosures of significant share ownership levels. It is not an annual report, earnings release, or management report, nor is it a proxy or voting result announcement. The content matches the definition of a Major Shareholding Notification (MRQ). The document length is substantial and contains detailed data, not just an announcement or certification, so it is not RNS or RPA.
2025-10-30 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is titled '주식등의 대량보유상황보고서' which translates to 'Report on Large Shareholding Status'. It contains detailed information about shareholdings, ownership percentages, related parties, and contractual details related to shareholding. It references specific legal provisions under the Capital Markets Act and includes data on shareholding changes, major shareholders, and related contracts. This type of document is a notification of changes in significant share ownership levels, typically required by regulatory authorities to disclose when a shareholder crosses certain ownership thresholds. It is not an annual report, earnings release, or any other financial report but a major shareholding notification. Therefore, the appropriate classification is Major Shareholding Notification (MRQ). The document length and detail support a high confidence in this classification.
2025-10-13 Korean
투자판단관련주요경영사항(임상시험결과) (조기난소부전 환자에서의 CordSTEM-ST의 안전성 및 내약성을 평가하기 위한 임상시험의 임상시험결과보고서(CSR) 수령)
Legal Proceedings Report Classification · 100% confidence The document is a formal regulatory filing from a Korean company (Cha Biotech) submitted to the Korea Exchange (KRX). It details the receipt of a Clinical Study Report (CSR) for a Phase 1 clinical trial. While it contains clinical data, it is structured as a 'Major Management Matter' disclosure (a standard regulatory filing format in Korea) rather than a standalone audit report or a scientific publication. Since it does not fit into specific categories like 10-K, Earnings Release, or Investor Presentation, and serves as a formal regulatory announcement of a material event, it is classified as a Regulatory Filing (RNS).
2025-09-18 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.